Scott K. Kindsfather, MD, medical director, Medical Oncology, Capital Health, discusses the evolution of reflex testing in lung cancer.

Currently, all resected specimens are being tested for PD-L1 levels and 

mutations, and the parameters of reflex testing will be moving targets going forward, Kindsfather says. As treatments currently being utilized in advanced settings are shifted up in the treatment paradigm, reflex testing will need to cover additional areas for new up-front therapies, Kindsfather concludes.

This information has been relayed to pathologists, and reflex testing will need to remain adaptive to keep pace with the treatment landscape, Kindsfather concludes.

Videos

Scott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.


Scott K. Kindsfather, MD

Articles

Dr. Kindsfather on the Evolution of Reflex Testing in Lung Cancer